Hua Medicine (02552) has filed its Monthly Return for Equity Issuer for the period ended 30 September 2026, indicating stable capital metrics and no share issuance or repurchase activity during the month.

Authorised and Issued Share Capital • Authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.001 each, equivalent to USD 2.00 million. • Issued share count was steady at 1.06 billion ordinary shares, with no treasury shares held. There were no increases or decreases in either issued or treasury shares.

Public Float Compliance • Hua Medicine confirmed adherence to the Main Board’s minimum public float requirement of 25% of issued shares, ensuring sufficient free float for trading.

Share Option Position • Under the Post-IPO Share Option Scheme (approved 26 August 2018, effective 14 September 2018), 77.51 million options were outstanding at month-end, representing approximately 7.34 % of issued shares. • No options were exercised in September; consequently, no new shares were issued and no funds were raised from option exercises. • The scheme still allows for the potential issuance of up to 16.71 million ordinary shares.

Other Equity Instruments and Corporate Actions • The company reported no outstanding warrants, convertible securities, or other equity-linked instruments. • There were no share repurchases, cancellations, or transfers of treasury shares during the reporting period.

With its share capital structure unchanged and public float comfortably above regulatory thresholds, Hua Medicine’s equity base remains stable as it enters the final quarter of 2026.